![Dr. Antonio Calles 🫁🚭 on Twitter: "Up to 6 ALK inhibitors fighting for pole position in 1L ALK+ lung cancer. R. Camidge #WCLC2016 #lcsm https://t.co/lmjXbpnkZU" / Twitter Dr. Antonio Calles 🫁🚭 on Twitter: "Up to 6 ALK inhibitors fighting for pole position in 1L ALK+ lung cancer. R. Camidge #WCLC2016 #lcsm https://t.co/lmjXbpnkZU" / Twitter](https://pbs.twimg.com/media/Cy1HYF0WQAE7K1N.jpg:large)
Dr. Antonio Calles 🫁🚭 on Twitter: "Up to 6 ALK inhibitors fighting for pole position in 1L ALK+ lung cancer. R. Camidge #WCLC2016 #lcsm https://t.co/lmjXbpnkZU" / Twitter
![Dr. Antonio Calles 🫁🚭 on Twitter: "RESILIENT: Liposomal Irinotecan versus Topotecan in Relapsed Small Cell Lung Cancer (SCLC). Neither OS, nor PFS gain. Doubled the risk of toxic deaths (8.4%). ❌ A Dr. Antonio Calles 🫁🚭 on Twitter: "RESILIENT: Liposomal Irinotecan versus Topotecan in Relapsed Small Cell Lung Cancer (SCLC). Neither OS, nor PFS gain. Doubled the risk of toxic deaths (8.4%). ❌ A](https://pbs.twimg.com/media/FseUv-aaUAIbZTP.jpg:large)
Dr. Antonio Calles 🫁🚭 on Twitter: "RESILIENT: Liposomal Irinotecan versus Topotecan in Relapsed Small Cell Lung Cancer (SCLC). Neither OS, nor PFS gain. Doubled the risk of toxic deaths (8.4%). ❌ A
![Martín Lázaro on Twitter: "Dr Rodríguez Abreu @delvysra : la importancia de los biomarcadores para predecir la respuesta a la #inmunoterapia en cáncer de pulmón #MD2021 #lcsm https://t.co/aAS6K4jnGH" / Twitter Martín Lázaro on Twitter: "Dr Rodríguez Abreu @delvysra : la importancia de los biomarcadores para predecir la respuesta a la #inmunoterapia en cáncer de pulmón #MD2021 #lcsm https://t.co/aAS6K4jnGH" / Twitter](https://pbs.twimg.com/media/FBwjPe0XMAUY09S.jpg)